Search results
Results From The WOW.Com Content Network
Anjalee Khemlani. Eli Lilly ( LLY) is riding high on its diabetes and weight-loss treatments Mounjaro and Zepbound — which Wall Street estimates could net the company $13.5 billion in 2024. "It ...
June 20, 2024 at 6:33 AM. (Reuters) -U.S. drugmaker Eli Lilly said on Thursday it was suing six more entities including medical spas and wellness centers for selling products claiming to contain ...
Updated January 4, 2024 at 3:47 PM. Drugmaker Eli Lilly announced on Thursday a new website that will allow patients to get a weight loss drug prescription through a telehealth provider — a move ...
Eli Lilly and Co. on Thursday warned against use of its popular diabetes and weight loss drugs Mounjaro and Zepbound for “cosmetic” reasons. The news comes as rampant demand for the reputed ...
By Divya Chowdhury and Patrick Wingrove. DAVOS, Switzerland (Reuters) -Eli Lilly on Tuesday said it plans to launch its weight-loss drug Mounjaro in new countries this year as it expands ...
Analysts expect sales to continue to build for Mounjaro and the company's weight-loss drug Zepbound, which regulators approved in November. Weight loss, diabetes drugs propel Eli Lilly to largely ...
Eli Lilly’s diabetes treatment Mounjaro, which is widely used for weight loss, raked in nearly $1 billion in second-quarter sales, or more than $200 million above what Wall Street had expected.
The frenzy for the drug has built up in recent months, with weight-loss-aiding drugs like Novo Nordisk’s Wegovy and Ozempic and Eli Lilly’s Mounjaro being touted as a “miracle.”